ARIA-Italy multidisciplinary consensus on nasal polyposis and biological treatments: Update 2025

IF 4.3 2区医学 Q2 ALLERGY

World Allergy Organization Journal Pub Date : 2025-05-01 DOI:10.1016/j.waojou.2025.101058

Carlo Lombardi MD , Rikki F. Canevari MD , Diego Bagnasco MD , Maria Beatrice Bilò MD , Giorgio Walter Canonica MD , Cristiano Caruso MD , Paolo Castelnuovo MD , Lorenzo Cecchi MD , Orietta Calcinoni MD , Mauro Carone MD , Marco Cassatella MD , Renato Cutrera MD , Gianni Danesi MD , Eugenio De Corso MD , Mario Di Gioacchino MD , Fabiano Di Marco MD , Stefania Gallo MD , Matteo Gelardi MD , Enrico Heffler MD , Clara Imperatore MD , M.T. Zedda

{"title":"ARIA-Italy multidisciplinary consensus on nasal polyposis and biological treatments: Update 2025","authors":"Carlo Lombardi MD , Rikki F. Canevari MD , Diego Bagnasco MD , Maria Beatrice Bilò MD , Giorgio Walter Canonica MD , Cristiano Caruso MD , Paolo Castelnuovo MD , Lorenzo Cecchi MD , Orietta Calcinoni MD , Mauro Carone MD , Marco Cassatella MD , Renato Cutrera MD , Gianni Danesi MD , Eugenio De Corso MD , Mario Di Gioacchino MD , Fabiano Di Marco MD , Stefania Gallo MD , Matteo Gelardi MD , Enrico Heffler MD , Clara Imperatore MD , M.T. Zedda","doi":"10.1016/j.waojou.2025.101058","DOIUrl":null,"url":null,"abstract":"<div><div>In recent years, it was recognized that type-2 inflammation connects nasal polyposis and severe asthma (SA) in addition to other type-2 diseases. Thus, some biological drugs developed for SA appeared to exert a favourable effect also in nasal polyposis. So far, there are several trials supporting this concept; therefore, some monoclonal antibodies already used for SA were assessed also in chronic rhinosinusistis with nasal polyposis (CRSwNP), with promising results.</div><div>Since different specialists are involved in the management of nasal polyposis (eg, pulmonologists, ENT specialists, allergists, immunologists, pediatricians), it was felt that an updated educational and informative document was needed to better identify the indications of biological therapies in nasal polyposis. We collected the main Italian scientific societies, and prepared (under the umbrella of Allergic Rhinitis and its Impact on Asthma, ARIA) a document endorsed by all societies, to provide a provisional statement for the future use of monoclonal antibodies (MAbs) as a medical treatment for polyposis, possibly associated with SA. The above mentioned document was the first endorsed document on this aspect, and the additional evidence required an update. The current pathogenic knowledge and the experimental evidence are herein reviewed, and some suggestions for a correct prescription and follow-up are provided.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 5","pages":"Article 101058"},"PeriodicalIF":4.3000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Allergy Organization Journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S193945512500033X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

In recent years, it was recognized that type-2 inflammation connects nasal polyposis and severe asthma (SA) in addition to other type-2 diseases. Thus, some biological drugs developed for SA appeared to exert a favourable effect also in nasal polyposis. So far, there are several trials supporting this concept; therefore, some monoclonal antibodies already used for SA were assessed also in chronic rhinosinusistis with nasal polyposis (CRSwNP), with promising results.

Since different specialists are involved in the management of nasal polyposis (eg, pulmonologists, ENT specialists, allergists, immunologists, pediatricians), it was felt that an updated educational and informative document was needed to better identify the indications of biological therapies in nasal polyposis. We collected the main Italian scientific societies, and prepared (under the umbrella of Allergic Rhinitis and its Impact on Asthma, ARIA) a document endorsed by all societies, to provide a provisional statement for the future use of monoclonal antibodies (MAbs) as a medical treatment for polyposis, possibly associated with SA. The above mentioned document was the first endorsed document on this aspect, and the additional evidence required an update. The current pathogenic knowledge and the experimental evidence are herein reviewed, and some suggestions for a correct prescription and follow-up are provided.

查看原文本刊更多论文

ARIA-Italy关于鼻息肉病和生物治疗的多学科共识：更新2025

近年来，人们认识到，除了其他2型疾病外，2型炎症还与鼻息肉病和严重哮喘（SA）有关。因此，一些为SA开发的生物药物似乎对鼻息肉病也有良好的作用。到目前为止，有几项试验支持这一概念；因此，一些已经用于SA的单克隆抗体也在慢性鼻窦炎伴鼻息肉病（CRSwNP）中进行了评估，结果很有希望。由于鼻息肉病的治疗涉及不同的专家（例如，肺科医生，耳鼻喉科专家，过敏症专家，免疫学家，儿科医生），因此需要更新教育和信息文件，以更好地确定鼻息肉病生物治疗的适应症。我们收集了意大利主要的科学学会，并准备了一份得到所有学会认可的文件（在过敏性鼻炎及其对哮喘的影响的保护伞下，ARIA），为将来使用单克隆抗体（mab）作为可能与SA相关的息肉病的医学治疗提供临时声明。上述文件是这方面的第一份认可文件，其他证据需要更新。本文综述了目前的病原学知识和实验证据，并对正确的处方和随访提出了一些建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World Allergy Organization Journal Immunology and Microbiology-Immunology

CiteScore

9.10

自引率

5.90%

发文量

审稿时长

9 weeks

期刊介绍： The official pubication of the World Allergy Organization, the World Allergy Organization Journal (WAOjournal) publishes original mechanistic, translational, and clinical research on the topics of allergy, asthma, anaphylaxis, and clincial immunology, as well as reviews, guidelines, and position papers that contribute to the improvement of patient care. WAOjournal publishes research on the growth of allergy prevalence within the scope of single countries, country comparisons, and practical global issues and regulations, or threats to the allergy specialty. The Journal invites the submissions of all authors interested in publishing on current global problems in allergy, asthma, anaphylaxis, and immunology. Of particular interest are the immunological consequences of climate change and the subsequent systematic transformations in food habits and their consequences for the allergy/immunology discipline.